These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25119810)

  • 1. [Immunoanalytical characteristics of galectin-3].
    Desbène C; Gaillard O
    Ann Biol Clin (Paris); 2014; 72(4):491-9. PubMed ID: 25119810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of galectin-3 in patients with heart failure.
    Bošnjak I; Selthofer-Relatić K; Včev A
    Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
    Gehlken C; Suthahar N; Meijers WC; de Boer RA
    Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis.
    Morrow DA; O'Donoghue ML
    J Am Coll Cardiol; 2012 Oct; 60(14):1257-8. PubMed ID: 22939562
    [No Abstract]   [Full Text] [Related]  

  • 5. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
    Meijers WC; van der Velde AR; de Boer RA
    Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical experience using galectin-3 in heart failure.
    McCullough PA
    Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 in cardiac remodeling and heart failure.
    de Boer RA; Yu L; van Veldhuisen DJ
    Curr Heart Fail Rep; 2010 Mar; 7(1):1-8. PubMed ID: 20425490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis.
    Chen A; Hou W; Zhang Y; Chen Y; He B
    Int J Cardiol; 2015 Mar; 182():168-70. PubMed ID: 25577755
    [No Abstract]   [Full Text] [Related]  

  • 11. Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes.
    Fu H; Nie S; Luo P; Ruan Y; Zhang Z; Miao H; Li X; Wen S; Bai R
    Biomark Med; 2020 Jul; 14(11):943-954. PubMed ID: 32940080
    [No Abstract]   [Full Text] [Related]  

  • 12. Galectin-3: a modifiable risk factor in heart failure.
    de Boer RA; van der Velde AR; Mueller C; van Veldhuisen DJ; Anker SD; Peacock WF; Adams KF; Maisel A
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):237-46. PubMed ID: 24789662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 in heart failure with preserved ejection fraction.
    de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
    Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
    Yu L; Ruifrok WP; Meissner M; Bos EM; van Goor H; Sanjabi B; van der Harst P; Pitt B; Goldstein IJ; Koerts JA; van Veldhuisen DJ; Bank RA; van Gilst WH; Silljé HH; de Boer RA
    Circ Heart Fail; 2013 Jan; 6(1):107-17. PubMed ID: 23230309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
    McCullough PA; Olobatoke A; Vanhecke TE
    Rev Cardiovasc Med; 2011; 12(4):200-10. PubMed ID: 22249510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalizing biomarker strategies in heart failure with galectin-3.
    Sherwi N; Merali S; Wong K
    Future Cardiol; 2012 Nov; 8(6):885-94. PubMed ID: 23176690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3: a novel mediator of heart failure development and progression.
    de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
    Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive review of the prognostic value of galectin-3 in heart failure.
    Coburn E; Frishman W
    Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intense sport practices and cardiac biomarkers.
    Le Goff C; Farré Segura J; Dufour P; Kaux JF; Cavalier E
    Clin Biochem; 2020 May; 79():1-8. PubMed ID: 32097617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.